- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02664467
Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project
In a 3 years longitudinal, observational, multicentre study, about 500 women will be recruited and followed-up from early pregnancy (10-15 gestational week) until 12 months after delivery. The primary aim of the present study is to systematically explore and characterize risk factors for perinatal depression (PND) by prospective sleep assessment (using wrist actigraphy, polysomnography and various sleep questionnaires) and blood based analysis of potential markers during the perinatal period (Life-ON study). Secondary aims are to explore the relationship between specific genetic polymorphisms and PND (substudy Life-ON1), to investigate the effectiveness of BLT in treating PND (substudy Life-ON2) and to test whether a short term trial of BLT during pregnancy can prevent PND (substudy Life-ON3).
The characterization of specific predictive and risk factors for PND may substantially contribute to improve preventive medical and social strategies for the affected women. The study results are expected to promote a better understanding of the relationship between sleep disorders and the development of PND and to confirm, in a large sample of women, the safety and efficacy of BLT both in prevention and treatment of PND.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ticino
-
Lugano, Ticino, Switzerland, 6900
- Neurocenter of Southern Switzerland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medically healthy
- Normal ocular function
- Gestational age between 10 to 15 weeks at time of screening
- Written informed consent
Exclusion Criteria:
- Diagnosis of bipolar I or II disorder (DSM-5)
- Recent history (less than 6 months) or current major depression or an Edinburgh Postnatal Depression Scale (EPDS) score > 12 at time of inclusion
- Any psychotic episode, substance abuse, recent history of suicide attempt (less than 12 months)
- Use of antidepressants or other pharmacologic treatments for depression in the last 6 months
- Fetal malformations and intrauterine fetal death
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bright light therapy (BLT)
Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
|
Bright light therapy (10'000 lux) for 60 minutes after wake-up
Placebo dim light (500 lux) for 60 minutes after wake-up
|
Placebo Comparator: Placebo dim light
Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
|
Bright light therapy (10'000 lux) for 60 minutes after wake-up
Placebo dim light (500 lux) for 60 minutes after wake-up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Depression Score as assessed by the Edinburgh Postnatal Depression Scale (EPDS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
|
during 6 weeks of light treatment plus 12 months observation
|
Change in Depression Score as assessed by the Hamilton Depression Rating scale - 21 items (HDRS-21)
Time Frame: during 6 weeks of light treatment plus 12 months observation
|
during 6 weeks of light treatment plus 12 months observation
|
Change in Depression Score as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
|
during 6 weeks of light treatment plus 12 months observation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective sleep-related markers and risk factors for perinatal depression as assessed by home polysomnography
Time Frame: at 23th-25th week of gestation
|
at 23th-25th week of gestation
|
Objective sleep-related markers and risk factors for perinatal depression as assessed by wrist actigraphy
Time Frame: observation over a period of 2 years
|
observation over a period of 2 years
|
Analysis of genetic risk factors for perinatal depression by single blood test
Time Frame: at 23th-25th week of gestation
|
at 23th-25th week of gestation
|
Subjective mood changes as assessed by the Visual Analog Scale for Depression (VAS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
|
during 6 weeks of light treatment plus 12 months observation
|
Number of participants with treatment-related adverse events as assessed by the Systematic Assessment for Treatment Emergent Events (SAFTEE)
Time Frame: during 6 weeks of light treatment plus 12 months observation
|
during 6 weeks of light treatment plus 12 months observation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORLugano
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Philips EnergyUp EnergyLight HF3419/01
-
Inha University HospitalCompletedStroke SequelaeKorea, Republic of
-
Meander Medical CenterCompleted
-
Goethe UniversityKing's College London; Radboud University Medical Center; Heidelberg University; Hospital Vall d'HebronCompletedDepression | Obesity | Attention-Deficit / Hyperactivity DisorderGermany, Netherlands, Spain, United Kingdom
-
University Medical Center GroningenCompletedSeasonal Affective Disorder